Literature DB >> 28208120

Cardiovascular Complications of HIV Infection.

Marshall J Glesby1.   

Abstract

HIV-infected individuals are at increased risk for cardiovascular events. Widely used cardiovascular disease (CVD) risk calculators to determine indications for statin treatment are not well validated for use in the HIV-infecte population. Some experts advocate including HIV infection as an independent risk factor for CVD. The effects of antiretroviral therapy on lipid profiles and the potentially increased risk for cardiovascular events must be taken into account when selecting treatment for HIV-infected individuals. There is increasing evidence that chronic immune activation and inflammation play a role in the pathogenesis of CVD in the context of HIV infection. This article summarizes a presentation by Marshall J. Glesby, MD, PhD, at the Ryan White HIV/AIDS Program Clinical Care Conference held in New Orleans, Louisiana, in December 2015.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28208120      PMCID: PMC5677048     

Source DB:  PubMed          Journal:  Top Antivir Med        ISSN: 2161-5853


  20 in total

1.  Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study.

Authors:  Colette Smith; Caroline A Sabin; Jens D Lundgren; Rodolphe Thiebaut; Rainer Weber; Matthew Law; Antonella d'Arminio Monforte; Ole Kirk; Nina Friis-Moller; Andrew Phillips; Peter Reiss; Wafaa El Sadr; Christian Pradier; Signe W Worm
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

2.  2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque.

Authors:  Markella V Zanni; Kathleen V Fitch; Meghan Feldpausch; Allison Han; Hang Lee; Michael T Lu; Suhny Abbara; Heather Ribaudo; Pamela S Douglas; Udo Hoffmann; Janet Lo; Steven K Grinspoon
Journal:  AIDS       Date:  2014-09-10       Impact factor: 4.177

3.  Arterial inflammation in patients with HIV.

Authors:  Sharath Subramanian; Ahmed Tawakol; Tricia H Burdo; Suhny Abbara; Jeffrey Wei; Jayanthi Vijayakumar; Erin Corsini; Amr Abdelbaky; Markella V Zanni; Udo Hoffmann; Kenneth C Williams; Janet Lo; Steven K Grinspoon
Journal:  JAMA       Date:  2012-07-25       Impact factor: 56.272

4.  Serious fatal and nonfatal non-AIDS-defining illnesses in Europe.

Authors:  Amanda Mocroft; Peter Reiss; Jacek Gasiorowski; Bruno Ledergerber; Justyna Kowalska; Antonio Chiesi; Jose Gatell; Aza Rakhmanova; Margaret Johnson; Ole Kirk; Jens Lundgren
Journal:  J Acquir Immune Defic Syndr       Date:  2010-10       Impact factor: 3.731

5.  Myocardial infarction among Danish HIV-infected individuals: population-attributable fractions associated with smoking.

Authors:  Line D Rasmussen; Marie Helleberg; Margaret T May; Shoaib Afzal; Gitte Kronborg; Carsten S Larsen; Court Pedersen; Jan Gerstoft; Børge G Nordestgaard; Niels Obel
Journal:  Clin Infect Dis       Date:  2015-01-16       Impact factor: 9.079

6.  A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study).

Authors:  Alain Nguyen; Alexandra Calmy; Cecile Delhumeau; Isabelle Mercier; Matthias Cavassini; Aurelie F Mello; Luigia Elzi; Andri Rauch; Enos Bernasconi; Patrick Schmid; Bernard Hirschel
Journal:  AIDS       Date:  2011-07-31       Impact factor: 4.177

7.  Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men.

Authors:  Markella V Zanni; Suhny Abbara; Janet Lo; Bryan Wai; David Hark; Eleni Marmarelis; Steven K Grinspoon
Journal:  AIDS       Date:  2013-05-15       Impact factor: 4.177

8.  National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report.

Authors:  Terry A Jacobson; Matthew K Ito; Kevin C Maki; Carl E Orringer; Harold E Bays; Peter H Jones; James M McKenney; Scott M Grundy; Edward A Gill; Robert A Wild; Don P Wilson; W Virgil Brown
Journal:  J Clin Lipidol       Date:  2015-04-07       Impact factor: 4.766

9.  CD4+ count-guided interruption of antiretroviral treatment.

Authors:  W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

10.  Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.

Authors:  Caroline A Sabin; Peter Reiss; Lene Ryom; Andrew N Phillips; Rainer Weber; Matthew Law; Eric Fontas; Amanda Mocroft; Stephane de Wit; Colette Smith; Francois Dabis; Antonella d'Arminio Monforte; Wafaa El-Sadr; Jens D Lundgren
Journal:  BMC Med       Date:  2016-03-31       Impact factor: 8.775

View more
  8 in total

1.  The Impact of Human Immunodeficiency Virus Infection on Gut Microbiota α-Diversity: An Individual-level Meta-analysis.

Authors:  Susan A Tuddenham; Wei Li A Koay; Ni Zhao; James R White; Khalil G Ghanem; Cynthia L Sears
Journal:  Clin Infect Dis       Date:  2020-02-03       Impact factor: 9.079

2.  Elevated Microparticle Tissue Factor Activity Is Associated With Carotid Artery Plaque in HIV-Infected Women.

Authors:  Juan Lin; Xiaonan Xue; Kathryn Anastos; Mardge H Cohen; Stephen J Gange; Jason M Lazar; Chenglong Liu; Wendy J Mack; Phyllis C Tien; Cathy Tilley; Howard N Hodis; Alan L Landay; Russell P Tracy; Robert C Kaplan; David B Hanna
Journal:  J Acquir Immune Defic Syndr       Date:  2019-05-01       Impact factor: 3.771

Review 3.  Macrophages and Phospholipases at the Intersection between Inflammation and the Pathogenesis of HIV-1 Infection.

Authors:  Francesca Spadaro; Serena Cecchetti; Laura Fantuzzi
Journal:  Int J Mol Sci       Date:  2017-06-29       Impact factor: 5.923

Review 4.  Ageing with HIV.

Authors:  Padraig McGettrick; Elena Alvarez Barco; Patrick W G Mallon
Journal:  Healthcare (Basel)       Date:  2018-02-14

Review 5.  NLRP3 Inflammasome Signaling as a Link Between HIV-1 Infection and Atherosclerotic Cardiovascular Disease.

Authors:  Caroline Mullis; Talia H Swartz
Journal:  Front Cardiovasc Med       Date:  2020-06-11

Review 6.  HIV, Combination Antiretroviral Therapy, and Vascular Diseases in Men and Women.

Authors:  Laszlo Kovacs; Taylor C Kress; Eric J Belin de Chantemèle
Journal:  JACC Basic Transl Sci       Date:  2022-01-19

7.  The data-collection on adverse effects of anti-HIV drugs (D:A:D) model for predicting cardiovascular events: External validation in a diverse cohort of people living with HIV.

Authors:  Ifedioranma Anikpo; Afiba Manza-A Agovi; Matthew J Cvitanovich; Frank Lonergan; Marc Johnson; Rohit P Ojha
Journal:  HIV Med       Date:  2021-08-19       Impact factor: 3.094

8.  Cardiac morbidity in HIV infection is associated with checkpoint inhibitor LAG-3 on CD4 T cells.

Authors:  Suresh Pallikkuth; Rajendra Pahwa; Bagavathi Kausalya; Shanmugam Saravanan; Li Pan; R Vignesh; Syed Iqbal; Sunil S Solomon; Kailapuri G Murugavel; Selvamuthu Poongulali; Nagalingeswaran Kumarasamy; Savita Pahwa
Journal:  PLoS One       Date:  2018-10-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.